Article

Lowering levels of arginase may halt progression of diabetic retinopathy

High levels of the enzyme arginase contributes to vascular eye damage, and therapies to lower its levels could halt progression of diabetic retinopathy, according to researchers at the Medical College of Georgia (MCG) School of Medicine.

Augusta, GA-High levels of the enzyme arginase contributes to vascular eye damage, and therapies to lower its levels could halt progression of diabetic retinopathy, according to researchers at the Medical College of Georgia (MCG) School of Medicine.

This is the first connection made between eye disease and arginase, an enzyme also known to cause cardiovascular disease, according to researchers.

To create an animal model of the inflammation that occurs early in vascular eye disease, researchers used bacterial proteins to produce uveitis, which also can cause blindness but is easier to detect and treat than diabetic retinopathy.

"It's taking L-arginine away from the nitric oxide synthase so it can accelerate wound healing, but the lack of substrate for nitric oxide synthase leads to vascular constriction and occlusion which causes further tissue damage, " said Ruth Caldwell, PhD, a cell biologist at the MCG School of Medicine and VA Medical Center, and the study's corresponding author.

As with arginase, some reactive oxygen species formation is a good thing but too much causes blood vessel damage, said researchers.

"Our studies demonstrate that if we inhibit arginase, we also reduce the reactive oxygen species level and vice versa," said Wenbo Zhang, PhD, postdoctoral fellow in Dr. Caldwell's lab and the paper's first author. "It appears that arginase and nitric oxide synthase influence each other in a positive feedback loop."

Rather than drugs that generally suppress arginase, the researchers want to find new drugs that can restore healthy levels of arginase.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) 50 years of ophthalmology: What changed the game (Part 2)
(Image credit: Ophthalmology Times) 50 years of ophthalmology: What changed the game? (Part 1)
(Image credit: Ophthalmology Times) From MIGS to gene therapy: Inder Paul Singh, MD, celebrates the past and future of glaucoma care
(Image credit: Ophthalmology Times) NeuroOp Guru: Using OCT to forecast outcomes in ethambutol optic neuropathy
(Image credit: Ophthalmology Times) Inside NYEE’s new refractive solutions center with Kira Manusis, MD
(Image credit: Ophthalmology Times) Dilsher Dhoot, MD, on the evolution of geographic atrophy therapy: where are we now?
© 2025 MJH Life Sciences

All rights reserved.